Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.65+0.02 (+1.23%)
Close on Nov 13, 2026Market cap $298.77MP/E –Yield –
Century Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Century Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$106.07M. For fiscal 2025 it was -$17.27M. The highest annual figure on record is -$17.27M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.27M | – |
| FY2024 | Dec 31, 2024 | -$138.14M | – |
| FY2023 | Dec 31, 2023 | -$146.55M | – |
| FY2022 | Dec 31, 2022 | -$133.83M | – |
| FY2021 | Dec 31, 2021 | -$94.88M | – |
| FY2020 | Dec 31, 2020 | -$53.90M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.21M | – |
| Q2 FY2026 | Jun 30, 2026 | -$36.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.68M | -131.9% |
| Q4 FY2025 | Dec 31, 2025 | -$20.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.66M | – |
| Q1 FY2025 | Mar 31, 2025 | $74.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.79M | – |
| Q2 FY2024 | Jun 30, 2024 | -$34.76M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.31M | – |
| Q4 FY2023 | Dec 31, 2023 | -$43.76M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.63M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$33.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$31.74M | – |
| Q2 FY2022 | Jun 30, 2022 | -$31.35M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.13M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.52M | – |
See a number that looks wrong?